Skip to main content

Table 1 Patient characteristics of the different treatment groups

From: A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa

  Inhalation Parenteral + Inhalation Parenteral All patients treated by Inhalation p-value (difference between groups?)
Number of patients (medical-surgical) 6 (1-5) 9 (5-4) 5 (3-2) 15 /
Age (years) 62.5 (15-84) 67.9 (59-76) 64.8 (46-77) 65.7 (15-84) 0.91
Gender (Male %) 66.7% 77.8% 60.0% 58% 0.83
SOFA-score at admission 5.2 (2-9) 6.4 (0-15) 10.0 (3-13) 5.9 (2-15) 0.18
SOFA-score start colistin 6.3 (1-15) 6.7 (2-11) 6.0 (3-9) 6.5 (1-15) 0.87
SAPS3-score 80.7 (70-88) 80.8 (70-95) 79.0 (73-85) 80.7 (70-95) 0.92
Length of stay (days) 55.0 (19-103) 73.0 (16-141) 40.0 (29-64) 65.8 (16-141) 0.16
Time between admission and development of the pneumonia (days) 28.0 (7-75) 25.1 (8-68) 19.6 (13-29) 16.7 (7-75) 0.99
Treatment duration (days) 27.2 (6-96) 19.3 (3-46) 21.0 (9-28) 22.5 (3-96) 0.87
Creatinine at onset colistin; RRT patients excluded (mg/dL) 0.8 (0.7-1.2) 2.3 (0.9-4.7) 0.9 (0.8-1.0) 1.6 (0.7-4.7) 0.39
Creatinine during colistin therapy; RRT patients exluded (mg/dL) 1.0(0.6-1.3) 2.6 (1.1-5.8) 1.9 (1.9-2.0) 1.9 (0.6-5.8) 0.36
Number of RRT patients 2/6 4/9 2/5 6/15 /
  1. Data are presented as mean values with the range between brackets. RRT: renal replacement therapy.